Avacta
AVA6000 shows signs of successful tumour targettingAvacta
Diagnostics business back into the spotlightAvacta
Diagnostics M&A-led growth strategy is ready to LaunchAvacta
Building Tx and Dx portfolios from proprietary platformsAvacta
AVA6000 set for third dose escalation stageAvacta
FY21 results: a year of frustrations and opportunitiesAvacta
AffiDX LFT sales paused to improve Omicron detectionAvacta
Consumer testing CE mark received for AffiDX LFTAvacta
AVA6000 set to start US Phase I studies in early-2022Avacta
Foundations for two healthy businesses now in place